MS Briefs

Core Temperature Not Elevated at Rest in RRMS

Mult Scler Relat Disord; ePub 2019 Jan 3; Chaseling, et al


 

Contrary to recent reports, resting core temperature is not elevated in patients with relapsing-remitting multiple sclerosis (RRMS) compared to healthy controls when measured using precision thermometry, according to a recent study. Furthermore, no association was observed between resting rectal temperature ( Tre) and any subjective measures of fatigue in a subset of participants with MS. Across 2 international data collection sites (Sydney and Dallas), 28 RRMS patients and 27 aged-matched controls (CON) were exposed to either 30°C, 30% relative humidity (RH) (Sydney) or 25°C, 30% RH (Dallas). Resting Tre and esophageal ( Teso) temperature and resting oxygen consumption (VO 2) was measured in MS (n=28) and CON (n=27) groups who completed the 25°C and 30°C trials. Tympanic membrane ( Ttym) temperature was measured in MS (n=16) and CON (n=15) groups in the 30°C condition. A modified fatigue impact scale (MFIS) questionnaire was used to assess subjective measures of psychosocial, physical, and cognitive fatigue in the 30°C condition. Researchers found:

  • Irrespective of ambient temperature, no group differences were observed for Tre, Teso, or resting VO 2.
  • Similarly, no group differences were observed for Ttym in the 30°C condition.

Chaseling GK, Allen DR, Vucic S, et al. Core temperature is not elevated at rest in people with relapsing-remitting multiple sclerosis. [Published online ahead of print January 3, 2019]. Mult Scler Relat Disord . doi:10.1016/j.msard.2019.01.013.

Recommended Reading

Real-world data reveal long-lasting effects achieved with RRMS treatments
ICYMI Multiple Sclerosis
Food allergies linked to increased MS relapses, lesions
ICYMI Multiple Sclerosis
Integrated analysis suggests cladribine’s safety in MS
ICYMI Multiple Sclerosis
Does rituximab delay disability progression in patients with secondary progressive MS?
ICYMI Multiple Sclerosis
Daclizumab beta may be superior to interferon beta on MS disability progression
ICYMI Multiple Sclerosis
Interferon Beta May Not Affect Pregnancy Outcomes in MS
ICYMI Multiple Sclerosis
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
ICYMI Multiple Sclerosis
DMTs, stem cell transplants both reduce disease progression in MS
ICYMI Multiple Sclerosis
Examining Pseudobulbar Affect in Multiple Sclerosis
ICYMI Multiple Sclerosis
Body Composition, Disability in People with MS
ICYMI Multiple Sclerosis